Daily Morning Note – 12 May 2020

PHILLIP SUMMARY

Wall Street stocks finished mixed on Monday as markets weigh hopes about reopening the economy against worries over coronavirus cases and the damage already inflicted by the shutdowns.

The Dow Jones Industrial Average ended down 0.5 per cent at 24,221.99.

The tech-rich Nasdaq Composite Index jumped 0.8 per cent to 9,192.34, while the broad-based S&P 500 ended essentially flat at 2,930.19.

Most US states have moved to reopen parts of their economy even as the national death toll approaches 80,000.

BREAKING NEWS

Swathes of Europe, as well as New York, began the long process of reopening from coronavirus lockdowns on Monday, but a resurgence of infections in China and South Korea offered a sobering reminder of the dangers of a second wave of cases.

Oil prices fell on Monday as investors worried about a second wave of coronavirus infections, but new output cuts from Saudi Arabia tempered worries about oversupply and limited price losses.

Mapletree North Asia Commercial Trust will issue its scrip dividend at a price of S$0.8752 per unit, the manager said on Monday night. The price tag represents a roughly 1.9 per cent discount on the volume-weighted average traded unit price for all trades in the 10 market days up until the books closed on Monday, the manager added.

Deloitte flags ‘going-concern’ uncertainty in IEV Holdings financial statements.

Trek 2000 International will likely post a first-quarter net loss for the three months to March 31, the board disclosed on Monday. Based on a preliminary review of its unaudited results, the board blamed lower fair value of the group’s investments for the expected quarterly loss, as it fingered “the negative impact to the investment and equity market” from the deadly coronavirus pandemic.

The board of troubled Ezion Holdings has warned of “a significant net loss” for the first quarter to March 31, in a bourse filing issued on Monday night.
The potential loss stems from an assessment of impairments on group assets. The assessment exercise was carried out after the coronavirus pandemic and plummeting oil prices “continued to adversely affect the reactivation and deployment plans of the group” and stymied its restructuring.

Hyphens Pharma International will reclassify its proposed final dividend for FY2019 as an interim dividend, as its annual general meeting, where shareholders would have voted on the payout, was delayed by the coronavirus pandemic. The books will now close on May 26, and shareholders can expect their payout of S$0.01 a share on June 8, Hyphens Pharma’s board said in a bourse filing on Monday.

Clearbridge Health will be a non-exclusive regional distributor of its Catalist-listed spin-off Biolidics’ coronavirus antibody test kits, according to bourse filings.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR

RESEARCH VIDEOS

Webinar Of The Week

Market Outlook: (PSR) DBS, UOB, OCBC, FCT, CMT, CCT, Ascendas REIT, ART, CAPL, SSG, STRH, NLT, VMS & Phillip Singapore Weekly

Date: 11 May 2020

For more on Market Outlook

Phillip Research in 3 minutes: #21 – Singapore REITs Sector

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information





Disclaimer
The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

 

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com